EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) today announced the appointment of Patrick James Doyle as Executive Vice President & Chief Business Officer. Doyle joins KineMed from PPD where he most recently served as Vice President, Strategic Partnerships.
At KineMed, Doyle will lead corporate development activities including licensing and strategic partnerships to enable the Company's vision of changing the way decisions are made in healthcare and wellness through the application of its proprietary kinetic proteomics platform and to expand on its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.
"Patrick brings over 18 years of broad pharmaceutical experience to KineMed, ranging from research and development to business development, licensing, alliance management, fund raising and running biotechs as a CEO," said David Fineman, Chairman and Chief Executive Officer of KineMed. "His expertise in forging broad strategic deals as well as developing licensing opportunities for pipeline expansion will be invaluable to KineMed as we continue our strategy of strategic pharmaceutical alliance product development (Rx), development of gold standard companion diagnostics in both pharma and wellness (Dx) and developing our own pipeline of ethical pharmaceutical products and wellness options for a healthier future (Tx)."
"I'm very excited to join KineMed and look forward to enabling the Company’s vision and establish important collaborations to advance and accelerate its 3 pronged strategy," said Doyle.
Prior to joining KineMed Doyle was President of Kareus Therapeutics, a clinical stage virtual biotech focused on Alzheimer’s and metabolic diseases from 2009 – 2013 and from 2006 – 2009 Doyle was CEO of Syntaxin, a privately held biotech which was sold to Ipsen for $265M in 2013.
Doyle held other significant senior positions. He was Global Head of Preclinical Partnering from 2000 to 2005 at F. Hoffmann-La-Roche, and at Novo Nordisk in Copenhagen, Denmark (1995-2000) he was scientific coordinator, and from 1990 to 1995 an investigator at the Laboratory of Metabolic Research in Geneva, Switzerland, in the area of metabolic diseases and brain function. He received his B.Sc (Hons) degree in pharmacology from the University of Sunderland in England where he also studied for a PhD and did postgraduate study at the University of Geneva, Switzerland where he specialized in neuronal pathways associated with metabolic regulation.
About KineMed, Inc.
KineMed is a growing health technology company that has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.
Using its patented technology, KineMed has developed analytic biomarker tests which measure, in a single sample, the rate of change of critical biological pathways. KineMed believes that its unique ability to measure the production and destruction of the key molecules involved in disease-modifying biological processes provides meaningful, and previously unavailable, information about both diseases and wellness, which can transform healthcare decisions. KineMed is expanding from its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.
For more information about KineMed, please visit: www.kinemed.com